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influence treatment outcome or treatment toxicity. Furthermore, no 
enhanced RBE was found for FFF compared to FF photon beams. 
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Purpose/Objective: Radiotherapy to collateral structures such as the 
carotid artery leads to atherosclerosis and increased stroke risk. 
Arterial thickening is a precursor to atherosclerosis. Carotid intima-
medial thickness (CIMT), a measure of arterial thickening, is a 
validated surrogate for prediction of cardio- and cerebrovascular 
events. Its application in irradiated arteries as a measure of 
accelerated atherosclerosis has shown variable results. This study 
investigates CIMT as an early marker of radiation-induced damage in 
head and neck cancer patients. 
Materials and Methods: Patients with head and neck cancer treated 
with a wedged-pair and matched neck technique or hemi-neck 
radiotherapy (unirradiated (unirr) side as control) at least 2 years 
previously were included. Patients had been prescribed a dose of at 
least 50 Gy to the neck. CIMT was measured on B-mode ultrasound 
using semi-automated detection software. Measurements were taken 
from the far wall in 4 arterial segments: proximal- (prox), mid-, distal 
(dist) common carotid artery (CCA), and bifurcation and were 
compared to corresponding segments in the unirr artery. CIMT 
measurements >75th percentile of a reference normal population were 
considered abnormal and at increased cardiovascular risk. 
Results: 24 patients (16 males) with a median age of 58 yrs 
(interquartile range (IQR) 49.2 – 64.2) were included. The mean 
maximum dose to the irradiated (irr) artery was 61.2 Gy (IQR 52.6 – 
61.8) and 1.1 Gy (IQR 1.0 – 1.8 Gy) to the unirr carotid artery. Mean 
CIMT was significantly greater in irr carotid arteries compared to unirr 
arteries: mid-CCA (0.75mm ± 0.2 (irr) vs 0.64mm ± 0.12 (unirr) (P = 
0.0057), distal CCA (0.79mm ± 0.24 (irr) vs 0.64mm ± 0.14 (unirr) (P = 
0.005), and bifurcation (0.85mm ± 0.28 (irr) vs 0.7mm ± 0.17 (unirr) (P 
= 0.0231). For the irr prox CCA, 23/24 (95.8%) had a CIMT > 75th 
percentile vs 16/24 (66.7%) for unirr prox CCA. For irr mid CCA, 20/24 
(83.3%) had CIMT >75th percentile vs 15/24 (62.5%) for unirr mid CCA. 
21/24 (87.5%) of irr dist CCA CIMT was >75th percentile vs 11/24 (45.8) 
for unirr dist CCA. For irr bifurcation, 15/21 (71.4%) had a CIMT >75th 
percentile vs 11.24 (45.8%) for unirr bifurcation. 
Conclusions: CIMT is increased in irr carotid arteries, suggesting this 
may be a useful marker of radiation-induced carotid atherosclerosis. 
The proximal CCA appears to be less sensitive to radiation-induced 
damage. 
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Purpose/Objective: This is the first report on the application and 
outcomes of hyperbaricoxygen therapy (HBO) for late adverse events 
which developed after proton or carbon-ionbeam radiation therapy. 
Materials and Methods: Between April 2008 and May 2012, 40 patients 
underwent HBO for late adverse events (105 episodes of 8 events) 
which developed more than 5 months after particle radiotherapy. 
There were 24 male and 16 female patients aged 15-83 years (median: 
67 years), and the performance state (PS) at the initiation of HBO 
was: PS0:PS1:PS2:PS3= 0:24:13:3. The primary diseases treated with 
particle radiotherapy were head-and-neck tumor in 23 patients, 
prostate cancer in 8, bone soft tissue tumor in 5, liver cancer in 4, 
and lung metastasis in 1. The late adverse events treated with HBO 
were classified into 8 events using CTC-AEver. 4.0. HBO was 
performed 3 times or more weekly, as a rule. The HBO chamber was 
compressed with 100% oxygen to 2.0 ATA inside, and the duration of 
treatment (pressure-keeping time) was 60 minutes. Responder of HBO 





HBO was initiated 5-64 months (median: 19 months) after particle 
radiotherapy. The total number of HBO was 4-120 (median: 29). Table 
shows grading score of late adverse events before and after HBO. 
Response rate (number of responder/total cases) of 8 events was: 
hematuria, 100% (4/4); rectal bleeding, 67% (4/6); pain, 56% (18/32); 
central nervous necrosis, 50% (2/4); mucosalulcer or fistula, 36% 
(8/22); mandibular bone necrosis, 28% (5/18); trismus, 15% (2/13); 
and skin ulcer, 0% (0/9). Total response rate was 40% (43/105). The 
average number of HBO was significantly higher in responder 
(69±48.9) than in non-responder (44±27.9) groups (p=.001). Adverse 
events due to ABO were minimal. Otitis media (non-infectious) 
occurred in 14 patients (35%) (Grade 1in 12 (30%), Grade 2 in 1 (2.5%) 
and Grade3 in 1 (2.5%)). TIA, diarrhea, bronchitis, cerebral infarction 
and sinusitis occurred in each one patient, however these events were 
transient and HBO did not be discontinued. 
Conclusions: HBO was effective for late radiation disorders after 
particle radiotherapy especially in hematuria, rectal bleeding, pain, 
and central nervous necrosis. Total response rate was 40% (43/105). It 
was suggested that many times (69±48.9) applications of HBO are 
necessary to obtain an effect.  
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Purpose/Objective: Numerous studies investigate the normal tissue 
dose-response relation. However, limited numbers of patients per 
study and the low incidence of toxicities render the relation 
uncertain. The aim of this study is to apply a statistical bootstrap 
analysis to evaluate the uncertainty in the predicted dose-response 
due to sampling variability. 
Materials and Methods: Two clinical endpoints were considered: 
myelopathy of the cervical spinal cord and pneumonitis. Data was 
taken from the recently published QUANTEC review. In order to 
evaluate the uncertainty in the clinical data, a Monte Carlo-based 
bootstrap analysis was applied. Ten thousand bootstrap replicates of 
the original dataset were produced by random sampling with 
replacement. This simulates alternative outcomes at each dose in a 
different sample of patients of the same size from the same 
population. The analysis requires only the dose, the number of 
patients, and the number of occurrences of the studied endpoint. The 
dose reported in the QUANTEC review was used: the equivalent dose 
given in 2-Gy fractions (EQD2) for the spinal cord, and the mean dose 
for the lung. Two dose-response models, a Poisson-based model and 
the Lyman model, were fitted to each bootstrap replicate using 
maximum likelihood. 
Results: The bootstrap analysis generates a family of curves 
representing the range of plausible dose-response relations. The 95% 
confidence intervals of the curve families for the two models overlap 
for doses included in the clinical study, but diverge beyond that. For 
higher doses, the Lyman model indicates a steeper slope than does 
the Poisson-based model. The bootstrap distributions of the model 
parameters D50 and y (m) indicate negative (positive) correlation. For 
both data sets, the likelihood of the observed data was higher for the 
Lyman model. This result was robust over the bootstrap analysis with 
higher likelihood of the Lyman model for over 90% of the bootstrap 
replicates, in both data sets. 
